67 results about "Lupus nephritis" patented technology

The application provides a preparation of a sema7A monoclonal antibody 8A12 and a treatment effect of the sema7A monoclonal antibody 8A12 on lupus nephritis, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 8A12 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein, can effectively inhibit the macrophage inflammatory response induced by Sema7A, and can continuously and effectively reduce serum anti-double-stranded DNA antibodies and kidney damage of lupus mice. The monoclonal antibody 8A12 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus and / or lupus nephritis thereof.

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to traditional Chinese medicine compound granules for treating lupus nephritis and a preparation method thereof. The formula of the traditional Chinese medicine compound granules comprises 25-35 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of salvia miltiorrhiza, 25-35 parts of artemisia apiacea, 12-18 parts of caulis sinomenii, 25-35 parts of centella asiatica, 25-35 parts of raw malt and 25-35 parts of euonymus alatus. The medicinal materials are subjected to water extraction, extracting solutions are combined and concentrated into extract, maltodextrin, microcrystalline cellulose and soluble starch are selected as auxiliary materials to be dried and granulated, and the prepared traditional Chinese medicine compound granules are low in fine powder proportion, high in hardness and short in dissolution time. By adopting the dosage form of granules, not only are the characteristics of quick absorption and quick action of the decoction maintained, but also the defects of inconvenience in decoction, large dosage and easiness in mildewing during temporary use of the decoction are overcome, and the curative effect is remarkably improved.

Provided herein are methods for treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in treating lupus nephritis, and FcRn antagonists for use in the manufacture of medicaments for treating lupus nephritis.

The invention relates to the technical field of medical image processing, in particular to a lupus nephritis curative effect prediction system based on multi-staining kidney biopsy pathological images. The system comprises a feature extraction module used for extracting image features of staining biopsy images of patients, a similarity analysis module used for distinguishing reference patients from non-reference patients according to the image features, a data preparation module used for forming training samples, and a data processing module used for processing the training samples. And the prediction module is used for performing model training based on the training data and predicting the healing probability of the target patient. According to the scheme, the model can be helped to pay more attention to training data of biopsy samples which are similar to biopsy samples of a target patient and are effectively different from biopsy samples of other reference patients, the characteristic of high heterogeneity existing in lupus nephritis is matched, the information mining effect of the biopsy sample image of lupus nephritis is improved, and the accuracy of the biopsy sample image of lupus nephritis is improved. And a doctor is assisted to accurately complete evaluation of specific typing and severity of lupus nephritis of a patient.

The invention discloses application of MMP-8 as a lupus nephritis marker and a medicine for inhibiting lupus nephritis, and belongs to the technical field of biomarkers. The expression characteristic, diagnostic value and pathogenic mechanism of MMP-8 in lupus nephritis are found for the first time, a new potential biomarker is provided for clinical diagnosis of LN, and the key effect of pDCs and MMP-8 in kidney injury of LN patients is disclosed; and a new angle is provided for preventing or inhibiting the lupus nephritis, so that the MMP-8 inhibitor can be screened or developed to treat the lupus nephritis.

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

Disclosed is a method for treating autoimmune diseases, wherein a therapeutically effective amount of a proteasome inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered to a patient with autoimmune diseases. This method has a certain therapeutic effect on patients with autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis (LN), and autoimmune hepatitis. The proteasome inhibitor or the pharmaceutically acceptable salt or pharmaceutical composition thereof has low toxicity, thereby showing excellent clinical application prospects.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

The invention relates to an application of a reagent for detecting SRC expression in preparation of a product for diagnosing and treating lupus nephritis, SRC is highly expressed in a patient with lupus nephritis, when the expression level of SRC is reduced, ferroptosis of podocyte is remarkably relieved, ferroptosis related markers are remarkably reversed, the levels of Fe < 2 + > and MDA are reduced, the level of GSH is increased, and compared with a control group, the SRC expression level is remarkably reduced. The viability of podocyte is increased; the invention relates to application of a reagent for detecting CYBB expression in preparation of a product for diagnosing and treating lupus nephritis, CYBB is highly expressed in a patient suffering from lupus nephritis, when the expression level of CYBB is reduced, ferroptosis in podocytes is remarkably relieved, ferroptosis related markers are remarkably reversed, the levels of ACSL4, Fe < 2 + >, ROS and MDA are reduced, and the levels of GPX4 and GSH are increased, so that the effect of treating lupus nephritis is achieved. The polarization of M2 macrophages is promoted, the ferroptosis phenomenon is further relieved through the polarization of the macrophages, and the viability of podocytes is improved.

A method of treating a subject suffering from an immune-mediated disease (e.g., IgA nephropathy, primary membranous nephropathy, an antibody-mediated rejection, lupus nephritis, systemic lupus erythematosus (SLE), Graves' Disease, Myasthenia Gravis, Anti-PLA2R positive Membranous Glomerulonephritis (aMN), Pemphigus, Sjögren's syndrome, and / or Anti-NMDA encephalitis) by administering to the subject a regimen of at least five doses of felzartamab and measuring a level of CD19+CD27hiCD38hi plasmablasts, a level of CD19+ B lymphocytes, or levels of CD19+CD27hiCD38hi plasmablasts and CD19+ B lymphocytes in a blood sample taken from the subject.

Provided herein are methods of treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of lupus nephritis and for use in the manufacture of a medicament for the treatment of lupus nephritis are also provided herein.

Provided herein are methods of treating subjects having or suspected of having an autoimmune disease (e.g., systemic lupus erythematosus and / or lupus nephritis) using natural killer (NK) cells, and related compositions, uses, and articles of manufacture. In some aspects, the NK cell expresses a recombinant receptor, such as a CD19 directed chimeric antigen receptor (CAR).

The present invention pertains to the technical field of biomedicine. Specifically disclosed is use of a substance for inhibiting the activity and / or expression of a CAPG gene or protein in the preparation of a product for treating renal fibrosis caused by kidney injury. First, research has found that CAPG is expressed at low levels in normal kidney tissues, while its expression level is increased in kidney tissues of patients with acute kidney injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic kidney disease, indicating that the expression of CAPG may be involved in the occurrence and development of renal fibrosis caused by kidney injury. Then, by means of constructing a CAPG knockout mouse model, it has been further found that knocking out CAPG can effectively alleviate the progression of renal fibrosis; and by means of culturing renal fibroblasts in vitro, it has been found that silencing or knocking down CAPG can inhibit TGF-β-induced activation of renal fibroblasts. The present invention is of great significance for the pathogenesis and treatment of kidney injury or renal fibrosis.

The application provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis. The application has the following beneficial effects: the TRPML1 specific small molecule inhibitor ML-SI3 can significantly reduce the serum anti-dsDNA antibody titer level of MRL / lpr lupus mice, reduce the urine albumin / creatinine ratio level, reduce the serum urea nitrogen level, reduce the swelling degree of the spleen and axillary lymph nodes, improve the kidney pathological changes, has a comprehensive protective effect on nephritis of MRL / lpr lupus mice, and provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis, provides a new medicine for treating lupus nephritis, and has good market value and clinical application prospect.

This invention provides the use of a reagent for detecting Effector CD4+ T cells in peripheral blood of subjects in the preparation of products for diagnosing membranous nephropathy, lupus nephritis, or ANCA-associated vasculitis. This invention also provides the use of peripheral blood Effector CD4+ T cells in the preparation of diagnostic models for membranous nephropathy, lupus nephritis, or ANCA-associated vasculitis. This invention detects this biomarker by flow cytometry, and the results show that Effector CD4+ T cells are significantly elevated in patients with membranous nephropathy, effectively distinguishing membranous nephropathy from healthy controls (validation set AUC 0.8098), and can help differentiate membranous nephropathy from lupus nephritis (validation set AUC 0.8686) and ANCA-associated vasculitis (validation set AUC 0.8968), and its level is correlated with the refractory nature of membranous nephropathy.

The application discloses application of a CK2 inhibitor CX4945 in preparation of a medicine for preventing and / or treating lupus nephritis, and provides the CK2 inhibitor CX4945 which can significantly reduce kidney immune complex and complement C3 deposition of a lupus animal model, effectively reduce a urine protein / cratin ratio, and has no obvious side effect, and can be prepared into a lupus immunotherapy medicine, and simultaneously provides a new combined treatment mode. The medicine can be prepared into an oral medicine, is convenient for treatment, and has high patient compliance.

The present disclosure relates to methods of diagnosing lupus nephritis or proliferative lupus nephritis in a subject, methods of predicting a subject's risk of developing lupus nephritis and methods of determine whether a subject suffering from lupus nephritis is responding to treatment. The methods herein involve detecting the presence of or level of at least one biomarker which is IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3, or a combination thereof.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

Disclosed in the present invention are a polymorph of a benzo[c]chroman compound, a preparation method therefor and use thereof. The present invention particularly provides a polymorph of a compound represented by formula I, a preparation method therefor and use thereof. The compound represented by formula I is used as a cathepsin C inhibitor, and a crystalline form of the compound and a pharmaceutical composition comprising the crystalline form can be used for treating asthma, obstructive pulmonary diseases, bronchiectasis, ANCA-related vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel diseases, rheumatic arthritis, rhinosinusitis, hidradenitis suppurativa or cancers.

Provided herein are methods for treating subjects having or suspected of having an autoimmune disease (e.g., systemic lupus erythematosus and / or lupus nephritis) using natural killer (NK) cells, as well as related compositions, uses, and products. In some embodiments, NK cells express recombinant receptors such as CD19-directed chimeric antigen receptors (CARs).

The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

Disclosed are methods for managing a treatment in an adult individual having systemic lupus erythematosus (SLE) undergoing therapy for lupus nephritis. In aspects, the method comprises detecting a level of each of neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and ceruloplasmin in a urine sample obtained from the individual, the levels of which are used to determine a score at a first time point and a second time point. Whether the individual is responding to the therapy, in particular an induction phase of a therapy, is determined based on a comparison of the first and second score. The therapy may then be continued or adjusted based on that determination.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating lupus nephritis and a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating lupus nephritis is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 8 to 12 parts of radix angelicae sinensis, 8 to 12 parts of radix salviae miltiorrhizae, 25 to 35 parts of herba artemisiae annuae, 12 to 18 parts of caulis sinomenii, 25 to 35 parts of herba centellae, 25 to 35 parts of raw fructus hordei germinatus and 25 to 35 parts of ramulus euonymi. The traditional Chinese medicine has the effects of eliminating and tonifying the whole prescription, not only aims at the superficial symptom of wind-damp heat toxin and blood stasis in an active period, but also considers the base deficiency of kidney deficiency and collateral stasis in a remission period, is matched with the core pathogenesis of deficiency, blood stasis and rheumatism interlaced of lupus nephritis, and has the effects of dispelling wind and eliminating dampness, tonifying kidney and qi, and removing blood stasis and dredging collaterals. Animal experiment results show that the traditional Chinese medicine composition can significantly reduce urine protein, dsDNA and ANA of lupus nephritis mice, and has a good pharmacodynamic effect.